9EN.F PHARVARIS N.V. EO -12
- Market cap
- EUR 2.16B
- P/E
- -
- P/B
- 7.02x
- ROE
- -57.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 9EN.F undervalued?
Graham numberThe Graham number of PHARVARIS N.V. EO -12 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PHARVARIS N.V. EO -12 fundamental analysis
No fundamental analysis for PHARVARIS N.V. EO -12 yet.
PHARVARIS N.V. EO -12 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase…
Full company profilePHARVARIS N.V. EO -12 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PHARVARIS N.V. EO -12 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -54.1M | -86.7M | -96.9M | -146M | -170M | -190M |
| EBITDA | - | -86.6M | -96.7M | -145M | -169M | -190M |
| Net Income | -42.7M | -76.3M | -101M | -134M | -176M | -174M |
| EPS | -1.29 | -2.26 | -1.93 | -2.47 | -2.69 | -2.49 |
| Balance Sheet | ||||||
| Total Assets | 212M | 168M | 399M | 291M | 301M | 329M |
| Total Liabilities | 7.14M | 18.5M | 14.6M | 23.6M | 30.2M | 27.9M |
| Shareholders' Equity | 205M | 149M | 384M | 268M | 271M | 301M |
| Cash & Short-term Investments | 209M | 162M | 391M | 281M | 292M | 318M |
| Cash Flow | ||||||
| Operating Cash Flow | -44.6M | -67.2M | -93.0M | -120M | -137M | -173M |
| Capital Expenditure | 130K | 124K | 90.0K | 538K | 165K | 158K |
| Free Cash Flow | -44.7M | -67.3M | -93.1M | -121M | -137M | -173M |
| Ratios | ||||||
| ROE | -20.8% | -51.1% | -26.3% | -50.1% | -64.8% | -57.9% |
| ROA | -20.1% | -45.5% | -25.3% | -46.1% | -58.3% | -53.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
PHARVARIS N.V. EO -12 dividends
PHARVARIS N.V. EO -12 has not paid dividends in the last 5 fiscal years.
Who owns PHARVARIS N.V. EO -12
- Insiders 6.31%
- Institutions 93.69%
- Public & others 0.00%
- Shares outstanding 70.2M
- Free float 44.1M
PHARVARIS N.V. EO -12 company profile
- Company name
- PHARVARIS N.V. EO -12
- Ticker
- 9EN.F
- ISIN
- NL00150005Y4
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 148
- Fiscal year end
- December
- Address
- Grafenauweg 8, Zug, Switzerland, 6300
- Phone
- 31 712036410
- Website
- pharvaris.com
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
PHARVARIS N.V. EO -12 management
10- Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, CEO & Executive Director · born 1959
- Dr. Peng Lu M.D., Ph.D.President · born 1978
- Mr. David W. Nassif J.D.CFO, Chief Legal Officer & Corporate Secretary · born 1954
- Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting Officer · born 1981
- Dr. Stefan Abele Ph.D.Chief Technology Operations Officer · born 1970
- Ms. Annick DeschoolmeesterChief Human Resources Officer · born 1973
- Dr. Anne A. Lesage Ph.D.Chief Early Development Officer · born 1961
- Mr. Wim Souverijns Ph.D.Chief Commercial Officer · born 1971
- Maggie BellerVP & Head of Corporate and Investor Communications
- Maryann CiminoDirector of Corporate Relations